Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR2B | P41595 | 4/20 | 0.50 |
| ▸ | PNMT | P11086 | 11/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11325445 | 0.82 | PNMT (0.60) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL3602160 | 0.81 | PNMT (0.49) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL3600557 | 0.81 | PNMT (0.49) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL3597388 | 0.79 | HTR2C (0.47) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL30139643 | 0.74 | HTR2A (0.75) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL6187756 | 0.74 | HTR2A (0.75) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL16269165 | 0.73 | HTR2A (0.55) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL11359434 | 0.73 | PNMT (0.73) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| SCHEMBL30487392 | 0.72 | HTR2A (0.54) | HTR2AHTR2CHTR2BPNMTADRA2A | |
| Hydrochloric Acid SCHEMBL38653706 | 0.72 | HTR2A (0.54) | HTR2AHTR2CHTR2BPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | HTR2A 1058/4885HTR2C 1168/4885HTR2B 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.